Roth Capital Maintains Buy On ANI Pharmaceuticals Ahead Of 2Q14 Results
Yesterday, Roth Capital analyst Scott Henry issued a note in which he maintained a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 price target. The call comes ahead of the upcoming second quarter results.
Henry wrote, “This quarter (2Q14) is expected to be filled with noise due to 1X stocking adjustments post the recent EEMT price increase (could remove ~$7 million from 2Q14 revenues), and 1X stock comp events (could result in a ~$2 million income statement hit this quarter, reported EPS could be negative $0.13). Our ongoing EPS from operations of $0.06 excludes the stock comp charge”. The analyst added, “We continue to view 2Q14 as a noisy quarter for ANIP and we focus investors on the long-term revenue and EPS outlook. Our long-term EPS targets remain unchanged and we maintain our Buy rating on shares of ANIP”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Scott Henry has a 21.7% average return and a 43% success rate. Henry has a -14.9% average return when recommending ANIP, and is ranked #371 out of 3207 analysts.